Paper2Agent-generated agents used AlphaGenome to prioritize GPR137 as the top predicted gene affected by psoriasis-associated variant rs887314 in CD4+ T cells, then integrated that prediction with existing MPRA-coupled scCRISPRi and CD4+ T-cell Perturb-seq data. A cross-screen correlation of gene-expression signatures supported GPR137 as the probable causal gene under stimulated conditions (Spearman rho 0.613 at 8 h and 0.630 at 48 h; FDR < 0.05), but not at rest. The paper presents this as activation-dependent computational evidence.
Technology: Paper2Agent-generated AlphaGenome, MPRA-coupled scCRISPRi and CD4+ T-cell Perturb-seq agents, coordinated through an AI co-scientist
Family AI Co-Scientist: profile · models page
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Paper2Agent-generated agents used AlphaGenome to prioritize GPR137 as the top predicted gene affected by psoriasis-associated variant rs887314 in CD4+ T cells, then integrated that prediction with existing MPRA-coupled scCRISPRi and CD4+ T-cell Perturb-seq data.
- Still unknown: The analysis reuses existing published datasets and does not report new wet-lab experiments for this psoriasis case. AlphaGenome supplied a model prediction; cross-dataset signature correlation supports, but does not establish, causal biology. The GPR137 concordance was significant only after stimulation, and the authors describe it as probable/activation-dependent. A human researcher selected which AI-proposed strategy to run. Primary paper source checked; no independent replication assessed.
- AI role: The AlphaGenome paper agent scored and ranked candidate genes at rs887314. Under human-in-the-loop supervision, the AI co-scientist inspected two other paper agents' datasets, proposed ten validation strategies, and the researcher selected signature-correlation analysis. The resulting cross-screen, cross-modality analysis found significant concordance for GPR137 only under stimulated conditions.
Evidence sources: https://www.nature.com/articles/s41586-026-11044-y
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In Gary Peltz's Stanford lab, two of the three existing drugs proposed by Co-Scientist blocked fibrosis and promoted regeneration in human liver cells, while Peltz's own two choices showed no benefit. The anticancer drug vorinostat blocked 91% of a damage response that can lead to scarring. Cell experiments only; published in Advanced Science.
Technology: Co-Scientist
Family AI Co-Scientist: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The anti-fibrotic efficacy and toxicity of 25 drugs were assessed serially in human liver organoids grown in microwells; Co-Scientist's candidates were tested in cells alongside the authors' own picks.
- Still unknown: Not reported.
- AI role: The AI co-scientist multi-agent system proposed three candidate drugs with reasoning, and helped direct their experimental characterization.
Evidence sources: https://deepmind.google/blog/uncovering-repurposed-medicines-to-fight-liver-fibrosis/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1002/advs.202508751&resultType=core&format=json
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 27 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Calico Life Sciences used Co-Scientist to formulate the hypothesis that metabolism regulates the cellular integrated stress response, refined experiments with the tool, and reports new findings. The post gives no numerical data, and the results have not yet been published or peer reviewed.
Technology: Co-Scientist
Family AI Co-Scientist: profile · models page
Publication: Announcement only · Test context: Test context unspecified in annotation. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: not reported
- Tested: Calico reports that experiments were run with the Co-Scientist hypothesis and produced new findings; the post does not describe the experiments, assays or results.
- Still unknown: Not reported (the results are not yet published; the team plans to publish them).
- AI role: Co-Scientist generated the hypothesis that metabolism regulates the integrated stress response, and was used to refine experimental design.
Evidence sources: https://deepmind.google/blog/opening-new-paths-in-aging-research/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 1/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Filippo Menolascina (Edinburgh) used Co-Scientist to search the literature for combinations of MASH therapies. The tool proposed the NLRP3 inflammasome as a link between inflammation and metabolism, and the post says the hypothesis was later tested experimentally. No numbers are given; the drug combinations were suggested for testing, not demonstrated.
Technology: Co-Scientist
Family AI Co-Scientist: profile · models page
Publication: Announcement only · Test context: Test context unspecified in annotation. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: not reported
- Tested: The article says the NLRP3 hypothesis was later experimentally verified but does not describe the experiments, who carried them out, or their results.
- Still unknown: Not reported (the article does not state limitations or whether the work is published).
- AI role: Co-Scientist searched the literature, proposed drug combinations for MASH therapy and proposed the NLRP3 inflammasome as the link between inflammation and metabolism.
Evidence sources: https://deepmind.google/blog/accelerating-discovery-of-liver-disease-mechanisms/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 1/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Omar Abudayyeh and Jonathan Gootenberg used Co-Scientist to search tens of thousands of papers, obtaining over 20 proposed genetic factors for reversing cellular aging, a couple of which were validated in the lab, and reducing analysis of genetic-screening data from six months to a few days. The post gives no sample size or peer review status.
Technology: Co-Scientist
Family AI Co-Scientist: profile · models page
Publication: Announcement only · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: direct test
- Tested: Lab tests validated a couple of the more than 20 proposed genetic factors, which pushed cells toward a younger state; the experiments and exact number are not described.
- Still unknown: Not reported (the post gives no sample size or peer-review status and contains only the investigators' quotes).
- AI role: Co-Scientist scanned tens of thousands of papers, proposed genetic factors for reversing cellular aging and analysed screening data alongside the literature.
Evidence sources: https://deepmind.google/blog/fast-tracking-genetic-leads-to-reverse-cellular-aging/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A system based on Gemini 2.0 that generates hypotheses and research proposals. In the lab, three drugs it suggested for repurposing against acute myeloid leukemia reduced cancer-cell viability, and all suggested treatments for liver fibrosis showed activity. Expert assessments covered only 11 targets; fibrosis results awaited a Stanford report.
Technology: AI co-scientist (Gemini 2.0, multi-agent)
Family AI Co-Scientist: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Elo auto-evaluation over 203 research goals; 15 expert-curated goals; blinded experts rated 11 goals (preference rank 2.36). In vitro on four AML cell lines: binimetinib, pacritinib, cerivastatin reduced viability; KIRA6 IC50 10 nM in KG-1a versus 180 nM in TK6. Seven combinations tested.
- Still unknown: The paper calls validation preliminary and in vitro only. KIRA6 was far less effective in MOLM-13 and HL-60. Expert evaluation was small and subjective; Elo is not ground truth. Liver fibrosis and AMR details are summarized only.
- AI role: A Gemini-based multi-agent system generated, debated and ranked hypotheses; experts selected candidates and prioritized lab experiments.
Evidence sources: https://doi.org/10.1038/s41586-026-10644-y
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.